Two epimers of siastatin B, 3-episiastatin B (3) and 3,4-diepisiastatin B (4), were obtained by the chemical modification of siastatin B. Compound3 showed marked inhibitory activity against influenza virus neuraminidases and significant inhibition of influenza virus infection in vitro.
Two integral membrane glycoproteins, haemagglutinin and neuraminidase, envelope the viral surface of influenza A and B. Infection by influenza virus begins with the binding of haemagglutinin to terminal sialic acid residues of glycoproteins on the surface of the host cell and subsequent fusion of viral and host cell membranes.X) Neuraminidase [EC 3.2.1.18] is a glycosidase, cleaving the a-2,3-and a-2,6-glycosidic linkages between terminal sialic acid and adjacent sugar residues of glycoproteins and glycolipids. 2) Neuraminidase is thought to facilitate the elution of progeny virus particles from the infected cells3) and the maintenance of mobility of progeny virus by prevention of self-aggregation.40 Thus neuraminidase may be an important factor in the spread of the infection.5) This suggests that a potent inhibitor for influenza virus neuraminidase could prevent or limit influenza infection. Manynaturally occuring and synthetic azasugars are potent and specific inhibitors for enzymes associated with carbohydrate metabolism, and they have the potential to produce a numberof kinds of beneficial therapeutic effects such as antiviral, antimetastatic, antifungal and antihyperglycemic activity, etc.6) One such, a multifunctional piperidine siastatin B (1), which was isolated as an inhibitor ofneuraminidase by Umezawaet al. 7) from a Streptomyces culture, structurally resembles sialic acid (TV-acetylneuraminic acid, 2).
In the course of our studies8~17) on the relationships between structure and biological activity of siastatin B (1), we have demonstrated that several analogues13~16) having the same equatorial carboxyl group as 1 show potent inhibitory activities for Streptococcus sp. and Clostridiumperfringens neuraminidases, f The synthesis of 3-episiastatin B analogues (3 and 4) were briefly communicated to Natural Products Lett.13) The anticlockwise numbering was used in Natural Products Lett.13) on siastatin B analogues according to the first report on isolation of siastatin B in J. Antibiotics.7) The correct clockwise numbering is employed for siastatin B analogues in this article according to IUPACrules. Therefore, 3-episiastatin B (3) and 3,4-diepisiastatin B (4), respectively, in this article are the same compoundsas 5-episiastatin B and 4,5-diepisiastatin B in Natural Products Lett.13) , NH) and 6.14 (dd, 7=7 and 3 Hz, H-6), indicative of Cf-conformer generally observed in the ring-imine protected siastatin B with carbamate fashion.10~12'16) The *H NMRspectrum of 8 is also indicative of the same conformer. Removal of the protecting groups of 7 and 8 by catalytic hydrogenolysis followed by acid hydrolysis gave 3 and 4 in good yields, respectively. The large coupling constants of 7=7.3 and 8 Hz between H-5 and H-6 in 3 and 4, respectively, are clearly indicative of C^-conformer in both compounds. Biological Activities The synthetic compounds (3 and 4) and the known sialidase inhibitor (ll) as the reference compound were tested for their inhibitory effects on AT-acetylneuraminidases of influenza viruses, Sendai virus and Newcastle disease virus. As shown in Table 1 the a-boat rather than the jS-chair conformation. It can be assumed that the monoepimeric 3 and the diepimeric 4 could change their conformation from chair to boat when in the enzyme, and the resulting equatorial groups in 3 would be more strongly stabilized by hydrogen bonding with the peptide of the influenza virus neuraminidase than those of 4. Asp 148 of influenza virus B/Beijing/1/87 neuraminidase18) could form a hydrogen bond to the 4-OH of3 similarly to 2-OH of2 in the boat conformations. As shown in Table 2 Melting points were determined with a Yanagimotoapparatus and were uncorrected. IR spectra were determined on a Hitachi Model 260-10 spectrophotometer. Optical rotations were measured with a Perkin-Elmer Model 241 polarimeter. *H NMRspectra were recorded with a JEOL JNMEX400 spectrometer. Chemical shifts are expressed in 3 values (ppm) with tetramethylsilane as an internal standard.
Mass spectra were taken by a JEOL JMS-SX102 in the FAB mode.
Viral Strains
The FM/1/47 (H1N1) and Kayano/57 (H2N2) strains of influenza A virus, the Lee/40 strain of influenza B virus, the Fushimi strain of Sendai virus, and the Miyadera strain of Newcastle disease virus (NDV)were used. Stocks of these viruses were all grown in the allantoic cavity of 10-day-old embryonated hen's eggs, and the allantoic fluids were harvested after incubation for 48 hours at 36°C. The viruses were purified partially from the allantoic harvests by differential centrifugations at 4,000 x g for 1 5 minutes and 33,000 x g for 1 hour, and the resulting virus pellets were further purified by centrifugation through a 5 to 40% potassium tartrate gradient at 25,000 x g for 2 hours. The virus-containing band was collected and centrifuged at 35,000 x g for 1 hour, and the resultant pellet was suspended in phosphate-buffered saline, pH 7.2 (PBS). The MDCK line of canine kidney cells was grown in Eagle's minimal essential medium (MEM) containing 10% bovine serum.
Neuraminidase Inhibition Assay
To 50//1 of the virus suspension containing 1 to 10^g of each virus was added an equal volume of the test sample at the final concentration of 100 fiM, and the mixture was incubated for 15 minutes at 37°C. The reaction mixture then received 100jul of fetuin solution (lOmg/ml) as the substrate either in 0.2m phosphate buffer pH 6.0 containing 2.5 mMCaCl2 (for influenza A and B viruses) or in 0.2 m acetate buffer pH 5.0 (for Sendai virus and NDV), and the mixture was further incubated at 37°C for 5 hours (influenza A and B viruses) or 3 hours (Sendai virus and NDV). Neuraminic acid liberated from the substrate was determined by the thiobarbituric acid method of Aminoff.21)
Haemagglutination Inhibition Assay The test sample (50piX) was serially diluted in two-fold steps with PBS and then mixed with an equal volume of the virus suspension containing 16HAunits of each virus. After incubation for 15 minutes at 4°C, lOOjul of chicken erythrocyte suspension (0.5% in PBS) was added to each mixture, and the HA patterns were read after a further incubation at 4°C for 1 hour.
Plaque Assay
The assay was carried out by the modified method of Schulman and Palese.22) Monolayers of MDCK VOL.46 NO. 12 THE JOURNAL OF ANTIBIOTICS 1887 cells were washed with Hank's BSS, and then incubated with 0.2ml of the mixture consisting of equal volumes of the virus suspension (50 PFU) and the test sample each prepared in Eagle's MEM.After adsorption for 1 hour at 34°C, the cell culture received 1.5 ml ofagar overlay medium consisting of Eagle's MEM,lOjUg/ml of Trypsin (DIFCO) and 0.8% Ager Noble. After incubation for 2 days at 34°C under 5% CO2 atmosphere, 1.5ml of the second agar overlay medium containing 0.001% Neutral Red was added, and the plaque numbers were counted on the next day. The test samples were included in both the first and second agar overlay media at the concentrations indicated in the text.
A^-(^rr-Butoxycarbonyl)-3,4-didehydro-4-deoxysiastatin B Benzyl Ester (6) To a solution of Af-(rm-butoxycarbonyl)-3,4-didehydro-4-deoxysiastatin B (5) (630mg) in DMF (6.3ml) were added diisopropylethylamine (3.5ml) and benzyl chloride (1.15ml), and the mixture was stirred at room temperature for 18 hours. Evaporation of the solvent gave an oil, which was dissolved in CHC13. The solution was washed with H2O, dried over MgSO4, and filtered. Evaporation of the filtrate gave an oil which was subjected to columnchromatography on silica gel. Elution with a mixture of CHCI3-CH3OH (10: 1) gave a colorless foamy glass of6 (747mg, 91%): 
4-0-Benzyl-7V-(terr-butoxycarbonyl)-3-episiastatin
B Benzyl Ester (7) and 4-0-Benzyl-iV-(terJ-butoxycarbonyl)-3,4-diepisiastatin B Benzyl Ester (8) To a solution of6 (710mg) in dry benzyl alcohol (8ml) was added K2CO3(800mg), and the mixture was stirred at room temperature overnight. The mixture was directly subjected to column chromatography on silica gel. Elution with a mixture of CHC13-CH3OH(30: 1) gave 7 (34mg, 3.8%) and 8 (437mg, 48.3%) as a colorless solid and a colorless foamy glass, respectively. 
3-Episiastatin B (3)
Compound 9 (12.8 mg) was dissolved in 4m hydrogen chloride in dioxane (0.25 ml), and the mixture was allowed to stand at room temperature for 4 hours. The resulting crystals were taken by centrifugation. The crystals were washed with dioxane to give a hydrochloride of 3 as hygroscopic crystals (9.9 mg, 97%): 
